Pharming Group NV (PHARM) — Capital Reinvestment Ratio

Latest as of September 2025: 0.00x

Pharming Group NV (PHARM) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow (€32.03 Million) in capital expenditures (€70.00K). See Pharming Group NV balance sheet quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

€32.03 Million
EUR

Capital Expenditures

€70.00K
EUR

Data as of

Sep 2025
Most recent filing

Pharming Group NV Capital Reinvestment Ratio (2017–2022)

This chart tracks Pharming Group NV's Capital Reinvestment Ratio across 6 annual periods. Check Pharming Group NV investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Pharming Group NV (2017–2022)

Year-by-year Capital Reinvestment Ratio for Pharming Group NV from 2017 to 2022. For live market cap and broader valuation context, see Pharming Group NV stock valuation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2022 0.09x €22.90 Million €1.98 Million ▼ -80.5%
2021 0.44x €36.13 Million €15.96 Million ▲ +144.0%
2020 0.18x €90.98 Million €16.47 Million ▼ -47.0%
2019 0.34x €74.56 Million €25.44 Million ▲ +265.6%
2018 0.09x €46.19 Million €4.31 Million ▼ -41.0%
2017 0.16x €45.84 Million €7.25 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow